The analysis revealed that the PCSK9 drug target is associated with an increased risk of cutaneous melanoma (OR, 1.56; 95% CI: 1.10–2.23; p = 0.013), as illustrated in Fig. 2. The gene discussed is PCSK9; the disease is cutaneous melanoma.